IP Library Granted Patent US 10,561,634
Granted Patent B2
US 10,561,634 · App. 16/447,557 · Granted Feb 18, 2020

Cannabinoid compositions and uses

Inventors: Alex Hearn (London, GB); Ritika Gupta (London, GB); Moira Bowdrey (Cambridge, GB)
Assignee: KIND CONSUMER LIMITED
A61K31/352A24F47/002A61K9/008A61K9/0073A61K9/12A61K9/1617A61K9/1623A61K31/05A61M11/02A61M15/00A61M15/009A61M15/0093A61M15/06A61M2202/0468
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,561,634
App. No.
16/447,557
Granted
Feb 18, 2020
Kind
B2
Abstract

An inhalable composition for use as a medicament in the treatment of a subject wherein said composition comprises: one or more cannabinoids or a pharmaceutically acceptable derivative or salt thereof; a propellant; a monohydric or polyhydric alcohol; and a glycol and/or glycol ether, characterised in that the ratio of monohydric or polyhydric alcohol to glycol or glycol ether by weight is from 6:1 to 1:1, wherein the composition is administered in the form of an aerosol having a fine particle fraction of 60% or more.

Claims (3)

1. A composition for alleviating one or more symptoms of Alzheimer's Disease in a human in need thereof consisting essentially of a nozzle, cannabis , propylene glycol, ethanol and at least 92% of a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof.

2. A composition for alleviating one or more symptoms of Alzheimer's Disease in a human in need thereof consisting essentially of a nozzle, synthetic cannabis , propylene glycol, ethanol and at least 92% of a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof.

3. A composition for alleviating one or more symptoms of Alzheimer's Disease in a human in need thereof consisting essentially of a nozzle, cannabis extract, propylene glycol, ethanol and at least 92% of a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof.

Assignments (2)
LICENSE Recorded Apr 20, 2020
From: KIND CONSUMER LIMITED
To: SENZER LIMITED
Reel/Frame 052440/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2019
From: HEARN, ALEX; GUPTA, RITIKA; BOWDREY, MOIRA
To: KIND CONSUMER LIMITED
Reel/Frame 049801/0114 →
Priority Claims (2)
GB 1402678.5 · Feb 14, 2014 · national
GB 1420943.1 · Nov 25, 2014 · national
Continuity (3)
Continuation 15118835
Provisional Application 61941724 · Feb 19, 2014
Related Publication 20190358195A1 · Nov 28, 2019